Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2024-07-26 Annual Report (ESEF)
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
DEU Medincell - exercice clos 31 mars 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2024-07-26 French
DEU Medincell - exercice clos 31 mars 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2024-07-26 French
Informations privilégiées / Autres communiqués
Net Asset Value Classification · 95% confidence The document is titled "Bilan semestriel du contrat de liquidité de la société MEDINCELL" (Semi-annual balance sheet of the MEDINCELL liquidity contract) and reports on the status of a liquidity contract as of June 30, 2024, comparing it to the previous period (December 31, 2023). This type of regular, periodic disclosure regarding market-making or liquidity agreements, often mandated by financial regulators (like the AMF mentioned), does not fit neatly into the primary financial report categories (10-K, IR) or standard corporate actions (DIV, CAP). It is a specific regulatory disclosure related to market operations. Since it is a specific, recurring report detailing financial/market activity that isn't a full financial statement or earnings release, it best fits the general 'Regulatory Filings' category (RNS) as a specific regulatory disclosure, or potentially a specialized 'Capital/Financing Update' (CAP) if the liquidity contract is viewed as a financing mechanism, but RNS is the safer fallback for specific, non-standard regulatory reports. Given the context of liquidity contract reporting, RNS (Regulatory Filings) is the most appropriate general classification for this specific type of mandated disclosure.
2024-07-11 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is titled "Half-year liquidity contract statement for MEDINCELL" and is dated July 11, 2024, reporting data as of June 30th, 2024. It details the status and activity (buy/sell side executions, shares, volume) under a liquidity contract with Kepler Cheuvreux, referencing AMF Decision N°2021-01. This type of regular, periodic disclosure concerning market operations and share liquidity management, often required semi-annually or quarterly, does not fit neatly into the primary financial report categories (10-K, IR) or specific corporate actions (DIV, CAP, SHA). It is a specific regulatory disclosure related to market practices. Given the options, it is a specialized regulatory filing that doesn't match the other specific categories like Earnings Release (ER), Interim Report (IR), or Director's Dealing (DIRS). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal, periodic statement mandated by a regulatory body (AMF) regarding market activity.
2024-07-11 English
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" dated July 1st, 2024. It announces that Medincell will present data and provide an overview of its R&D programs at the upcoming CRS 2024 conference. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing financial results (ER/IR). It is an announcement about future scientific/corporate activities and presentations. Since it is a general corporate announcement that doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate announcements not covered elsewhere, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of participation in a conference where presentations will occur. Given the nature of a press release announcing participation in a scientific conference, RNS is the best fit as a general corporate/regulatory update.
2024-07-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) dated July 1, 2024. It announces that Medincell will present R&D data, including oncology findings and updates on its BEPO® technology, at the upcoming CRS 2024 conference. This is a short announcement detailing upcoming events and research highlights, not the full financial report (10-K or IR) or a transcript of a call. Since it is an announcement about company activities and scientific progress, and it doesn't fit the specific categories like Earnings Release (ER) or Management Discussion (MDA), it falls best under the general category for regulatory/corporate announcements that aren't strictly financial results or mandatory filings, which points towards Regulatory Filings (RNS) as a broad fit, or potentially Investor Presentation (IP) if it were the presentation itself. However, as a press release announcing participation and data presentation, RNS is the most appropriate general classification for non-standard corporate news releases that aren't explicitly defined elsewhere. Given the content focuses heavily on R&D progress and conference participation, it is a corporate communication, best categorized as RNS (Regulatory Filings/General Announcement) or potentially IP if the focus was solely on the presentation material, but RNS covers general press releases well.
2024-07-01 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.